We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Chemotherapy Response Linked to Two Genes

By Biotechdaily staff writers
Posted on 23 Jun 2004
Cancer researchers have shown that genetic variation in two genes that code for DNA repair enzymes are linked to the survival time of patients receiving platinum-based chemotherapy for nonsmall cell lung cancer (NSCLC).

Investigators at Massachusetts General Hospital (Boston, USA) used polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) to evaluate genetic polymorphisms of the XPD (Asp312Asn) and XRCC1 (Arg399Gln) DNA repair genes in 103 patients with stage III (54%) and IV (46%) NSCLC treated with platinum-based chemotherapy.

They reported in the June 1, 2004, online edition of the Journal of Clinical Oncology that while patients with no variations survived a median of 20.4 months, those with a total of three variations in the XPD and XRCC1 genes survived a median of 6.8 months. More...
Patients with one variation survived 16.6 months, while those with two variations survived a median of 11 months.

The number of genetic variations present independently predicted length of survival irrespective of the patients' ability to carry out daily activities, their stage of disease, or the type of chemotherapy they received.
"The concept of selecting a chemotherapy drug based on a patient's genetic make-up is relatively new and very exciting,” said first author Dr. Sarada Gurubhagavatula, a physician at Massachusetts General Hospital. "We hope that this type of research will one day enable doctors and patients to make more informed decisions about chemotherapy treatments.”




Related Links:
Massachusetts General Hospital

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Multi-Chamber Washer-Disinfector
WD 390
New
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.